

AMENDMENTS TO THE CLAIMS

The following Listing of Claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (previously presented): Antibody for the diagnosis or treatment of neuropsychiatric diseases, wherein the antibody recognizes misfolded proteins that can be assigned specifically to one of the diseases.

Claim 2 (currently amended): Antibody according to ~~Claim~~ claim 1, wherein the disease is schizophrenia.

Claim 3 (currently amended): Antibody according to ~~Claim~~ claim 1, wherein the disease is depression.

Claim 4 (currently amended): Antibody according to ~~Claim~~ claim 1, wherein the disease is a bipolar affective disorder.

Claim 5 (previously presented): Antibody according to claim 1, wherein the antibody recognizes misfolded proteins that are specific for multiple diseases, whereby the assignment to a disease can be made by means of further properties of the protein and/or by means of its origin.

Claim 6 (previously presented): Antibody according to claim 1, wherein the antibody is obtained by immunization of suitable animals with purified brain fractions of patients afflicted by a neuropsychiatric disease, whereby steps that effect an enrichment of misfolded proteins are provided in the purification.

Claim 7 (previously presented): Antibody according to claim 6, wherein a purification step with ionic detergents is provided in the purification.

Claim 8 (previously presented): Antibody according to claim 7, wherein the purification step is carried out at 0-10 °C.

Claim 9 (previously presented): Antibody according to claim 7, wherein the ionic detergent used in the purification step is used at a concentration between 0.2 and 2%.

Claim 10 (previously presented): Antibody according to claim 7, wherein the ionic detergent used in the purification is sarcosyl.

Claim 11 (previously presented): Antibody according to claim 7, wherein the purification step with an ionic detergent comprises an ultracentrifugation step at at least 100,000 x g.

Claim 12 (previously presented): Antibody according to claim 6, wherein a purification step with β-sheet-binding substances such as Congo red, thioflavine or β-sheet-binding peptides is provided in the purification, wherein these substances or peptides may be immobilized, if applicable.

Claim 13 (previously presented): Antibody according to claim 6, wherein a protease digestion step at a temperature of 0-10°C is provided in the purification.

Claim 14 (previously presented): Antibody according to claim 1, wherein the antibody is a monoclonal antibody.

Claim 15 (previously presented): Antibody according to claim 1, wherein the antibody is a conformation-specific monoclonal antibody.

Claim 16 (previously presented): Antibody according to claim 1, wherein the antibody is a recombinant antibody.

Claim 17 (previously presented): Antibody according to claim 1, wherein the antibody is a blood-brain barrier-crossing antibody.

Claim 18 (previously presented): Antibody according to claim 1, wherein the antibody is a chimeric or humanized antibody.

Claim 19 (previously presented): Antibody according to claim 1, wherein the antibody is an antibody fragment.

Claim 20 (previously presented): Antibody according to claim 1, wherein the antibody is coupled to a pharmaceutically active substance.

Claim 21 (previously presented): Antibody according to claim 1, wherein the antibody is coupled to an isotope or a radioactive labeled molecule.

Claim 22 (previously presented): Antibody termed 7B2 that can be produced by hybridoma cells that are deposited under the number, DSM ACC2713, for diagnosis or treatment of diseases, in particular of neuropsychiatric diseases, such as schizophrenia or depression or bipolar affective disorder.

Claim 23 (previously presented): Antibody termed 9C9 that can be produced by hybridoma cells that are deposited under the number, DSM ACC2714, for diagnosis or treatment of diseases, in particular of neuropsychiatric diseases, such as schizophrenia or depression or bipolar affective disorder.

Claim 24 (previously presented): Method for diagnosis of neuropsychiatric diseases, such as schizophrenia or depression or bipolar affective disorder, by means of antibodies that bind to neuropsychiatric disease-specific proteins, in which method

- a) the antibodies are contacted with a tissue or body fluid sample of a patient,
- b) antibody-protein complexes thus formed, if any, are detected, and

- c) the presence, if applicable, of antibody-protein complexes is considered to be a positive finding for a neuropsychiatric disease,
wherein
- d) an antibody that recognizes misfolded proteins that can be assigned specifically to one of the diseases is used in the method.

Claim 25 (currently amended): The method according to Claim claim 24, wherein the presence of antibody-protein complexes is detected by means of ELISA, Western blotting or immuno-coupled fluorescence methods.

Claim 26 (previously presented): The method according to claim 24, wherein the positive finding for a neuropsychiatric disease is a diagnosed predisposition and/or a positive diagnosis for one of the diseases, schizophrenia or depression or bipolar affective disorder.

Claim 27 (previously presented): The method according to claim 24, wherein the body fluid sample to be tested is liquor, urine, blood or serum.

Claim 28 (currently amended): ~~Use of antibodies according to claim 1, for producing a~~ pharmaceutical preparation that can be administered to ~~the~~ a patient, in particular in a blood-brain barrier-crossing form~~[,]~~ for treatment of the neuropsychiatric diseases schizophrenia or depression or bipolar affective disorder comprising antibodies according to claim 1.

Claim 29 (currently amended): ~~Use according to Claim~~ The pharmaceutical preparation according to claim 28, wherein the antibodies are coupled to pharmaceutically active substances.

Claim 30 (currently amended): ~~Use according to Claim~~ The pharmaceutical preparation according to claim 28, wherein the antibodies are coupled to isotopes or radioactively labeled molecules.

Claim 31 (currently amended): ~~Use of small-molecule, blood-brain barrier-crossing agents that can be administered to the patient, for producing a~~A pharmaceutical composition that can be administered to a patient in a blood-brain barrier-crossing form[[,] for treatment of the neuropsychiatric diseases, schizophrenia or depression or bipolar affective disorder wherein the comprising small molecule, blood-brain barrier-crossing agents that recognize misfolded proteins that can be assigned specifically to one of the diseases.

Claim 32 (currently amended): ~~Use according to Claim~~The pharmaceutical composition according to claim 31, wherein the small-molecule agents are organic molecules that bind specifically to epitopes that are recognized by the antibodies.

Claim 33 (currently amended): ~~Use~~The pharmaceutical composition according to claim 31, in which the agents comprise multiple ligands that are connected to each other by spacers, and said ligands each bind specifically to various, non-overlapping epitopes that are recognized by the agents.

Claim 34 (currently amended): ~~Use of immunogenic substances that elicit an immune response such that the immune system of a patient forms antibodies against misfolded proteins according to Claim 1, for producing a~~A pharmaceutical composition that can be administered to a patient in a blood-brain barrier-crossing form[,:] for treatment of the neuropsychiatric diseases schizophrenia or depression or bipolar affective disorder comprising immunogenic substances that elicit an immune response such that the immune system of the patient forms antibodies against misfolded proteins according to claim 1.

Claim 35 (currently amended): ~~Use according to Claim~~The pharmaceutical composition according to claim 34, wherein the immunogenic substances are misfolded proteins or fragments that can be assigned to one of the diseases, schizophrenia or depression or bipolar affective disorder.